Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies

PURPOSE: Complement alternative pathway (AP) dysregulation has been implicated in geographic atrophy, an advanced form of age-related macular degeneration. Danicopan is an investigational, first-in-class inhibitor of factor D, an essential AP activation enzyme. We assessed danicopan distribution to...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyer, David D., Ko, Ya-Ping, Podos, Steven D., Cartwright, Mark E., Gao, Xiang, Wiles, Jason A., Huang, Mingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Retina
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624268/
https://www.ncbi.nlm.nih.gov/pubmed/36301553
http://dx.doi.org/10.1167/tvst.11.10.37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624268/
https://www.ncbi.nlm.nih.gov/pubmed/36301553
http://dx.doi.org/10.1167/tvst.11.10.37

Ejemplares similares